Position
Squarepoint Ops LLC in Kymera Therapeutics, Inc.
Back to the book · All holders of KYMR
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $70.4K$77.81 → $83.29
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 159.4K | $12.4M | — | — | — | 0.0% |
| Q1 2026 | 12.8K | $1.07M | $83.29 | $70.4K | −$11.4M | 0.0% |